Novo Nordisk Plans Q1 Launch Of Long-Acting Insulin Tresiba
This article was originally published in The Pink Sheet Daily
Executive Summary
After initial rejection and resubmission, FDA approves ultra-long-acting insulin Tresiba, and also Ryzodeg, which combines Tresiba and the company’s meal-time insulin NovoLog.
You may also be interested in...
Hanmi’s Once Weekly Efpeglenatide Bests Liraglutide In Phase II
In its ongoing push to seek a global partner for its diabetes therapies, South Korea's major pharma firm Hanmi has presented the results of Phase IIb study for a once weekly form of its diabetes therapy efpeglenatide, which showed benefits over Novo Nordisk’s rival therapy Victoza.
Lilly and Boehringer Ingelheim Launch Biosimilar Lantus In UK, Germany
The cost of biosimilar Lantus to payers is at around a 15% discount to the originator product in the UK, but cost-savings are expected to vary across Europe as supply contracts with health insurers and hospitals are negotiated.
Novo Nordisk Dismayed By “Complete Response” Letter For Insulin Degludec
FDA is requesting data from a dedicated cardiovascular outcomes trial before approving the ultra-long-acting insulins Tresiba and Ryzodeg. News of the regulatory setback caused a 13% drop in the company’s stock price on Feb. 11.